Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Telix Pharmaceuticals ( (AU:TLX) ).
Telix Pharmaceuticals announced that its next-generation PSMA PET imaging agent, Gozellix, has been granted a permanent HCPCS code by the U.S. Centers for Medicare & Medicaid Services, effective from October 1, 2025. This milestone supports provider billing and reimbursement, facilitating clinical adoption and expanded access to PSMA PET imaging for prostate cancer patients in the U.S., and marks an important step in Telix’s mission to improve access to precision medicine imaging.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$26.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Headquartered in Melbourne, Australia, Telix operates internationally in the United States, Brazil, Canada, Europe, and Japan. The company aims to address significant unmet medical needs in oncology and rare diseases with its clinical and commercial stage products.
Average Trading Volume: 1,384,665
Technical Sentiment Signal: Buy
Current Market Cap: A$8.14B
For detailed information about TLX stock, go to TipRanks’ Stock Analysis page.